Expert Review of Pharmacoeconomics & Outcomes Research最新文献_第7页

Expert review of pharmacoeconomics and outcomes research: high impact articles from 2024. 药物经济学和结果研究专家综述：2024年以来高影响力文章。

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-07-01 Epub Date: 2025-04-29 DOI: 10.1080/14737167.2025.2496217

Mickaël Hiligsmann, Carolyn Gotay, Jayashri Sankaranarayanan, Carlo Lazzaro, Tamas Agh, Lieke Maas, John Yfantopoulos, Rob McMinn

引用次数: 0

Future directions for the economics of prevention. 预防经济学的未来方向。

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-07-01 Epub Date: 2025-04-27 DOI: 10.1080/14737167.2025.2498665

Bram Wouterse, João Vasco Santos, Mickaël Hiligsmann

引用次数: 0

Cost-effectiveness analysis of adagrasib with or without cetuximab in the treatment of colorectal cancer patients with mutated KRAS G12C. 阿达格拉西联合或不联合西妥昔单抗治疗KRAS G12C突变的结直肠癌患者的成本-效果分析

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-06-23 DOI: 10.1080/14737167.2025.2521439

Ruihong Yao, Yao Yao, Xue Teng, Yao Jin, Shangwei Guan, Mei Dong, Tong Liu

{"title":"Cost-effectiveness analysis of adagrasib with or without cetuximab in the treatment of colorectal cancer patients with mutated KRAS G12C.","authors":"Ruihong Yao, Yao Yao, Xue Teng, Yao Jin, Shangwei Guan, Mei Dong, Tong Liu","doi":"10.1080/14737167.2025.2521439","DOIUrl":"10.1080/14737167.2025.2521439","url":null,"abstract":"Objectives: This study evaluates the cost-effectiveness of adagrasib plus cetuximab in contrast to adagrasib monotherapy in treating colorectal cancer (CRC) patients with mutated KRASG12C from the perspective of healthcare payers in the USA.Methods: An economic evaluation utilizing a 3-state partitioned survival model assessed the cost-effectiveness of adagrasib plus cetuximab versus adagrasib monotherapy. The Kaplan-Meier curves for overall survival (OS) and progression-free survival (PFS) from a clinical trial were digitally extracted, and the Log-Logistic model was employed at the end of the trial to extrapolate the long-term survivals.Results: The estimated cost for adagrasib plus cetuximab treatment was higher than that of adagrasib monotherapy (290,645.434 USD vs 188,837.346 USD). The estimated utility was decreased compared to that of adagrasib monotherapy treatment (1.094 QALYs vs 1.359 QALYs). The ICER was calculated at -384,674.32 USD/QALY, suggesting the adagrasib plus cetuximab therapy did not demonstrate an economic advantage over adagrasib monotherapy for CRC patients with mutated KRASG12C.Conclusion: Adagrasib plus cetuximab was not cost-effective compared to adagrasib monotherapy as a late-line treatment for advanced or metastatic CRC patients with mutated KRASG12C in the USA.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-9"},"PeriodicalIF":1.8,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144301477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cost-effectiveness analysis of sotorasib plus panitumumab in the treatment of refractory colorectal cancer with mutated KRAS G12C in the USA. sotorasib联合帕尼单抗治疗美国KRAS G12C突变的难治性结直肠癌的成本-效果分析

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-06-17 DOI: 10.1080/14737167.2025.2521444

Tong Liu, Yao Yao, Xue Teng, Zhiqiang Tong, Mei Dong, Ruihong Yao

{"title":"Cost-effectiveness analysis of sotorasib plus panitumumab in the treatment of refractory colorectal cancer with mutated KRAS G12C in the USA.","authors":"Tong Liu, Yao Yao, Xue Teng, Zhiqiang Tong, Mei Dong, Ruihong Yao","doi":"10.1080/14737167.2025.2521444","DOIUrl":"10.1080/14737167.2025.2521444","url":null,"abstract":"Background: This study evaluates the cost-effectiveness of sotorasib plus panitumumab in contrast to standard care in the treatment of refractory colorectal cancer (CRC) with mutated KRASG12Cfrom the perspective of healthcare payers in the U.S.A.Research design and methods: An economic evaluation utilizing a 3-state partitioned survival model assessed the cost-effectiveness of sotorasib plus panitumumab versus standard care. TheKaplan-Meier curves for overall survival (OS) and progression-free survival(PFS) from a clinical trial were digitally extracted, and the Log-Logistic model was employed at the end of the trial to extrapolate the long-term survivals.Results: The estimated cost for sotorasib plus panitumumab treatment was higher than that of standard care treatment (77,087.936 USD vs 8905.065 USD). In addition, the estimated utility was relatively augmented than that of standard care treatment (0.876 QALYs vs 0.857 QALYs). The ICER was calculated at 3,551,555554USD/ QALY, suggesting the sotorasib plus panitumumab therapy did not demonstrate an economic advantage over standard care therapy for refractory CRC patients with mutated KRASG12C at the threshold of 150,000 USD/ QALY.Conclusions: Sotorasib plus panitumumab did not demonstrate an economic advantage compared to standard care in the treatment of refractory CRC with mutated KRASG12C in the U.S.A.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-9"},"PeriodicalIF":1.8,"publicationDate":"2025-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144301478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cost-utility analysis of osimertinib and dacomitinib in the first-line treatment of advanced non-small cell lung cancer with EGFR mutation. 奥西替尼和达科替尼一线治疗晚期非小细胞肺癌EGFR突变的成本-效用分析。

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-06-17 DOI: 10.1080/14737167.2025.2518135

Lili Su, Xiangyu Zhang, Mengrong Li, Ying Li, Dong Wang

{"title":"Cost-utility analysis of osimertinib and dacomitinib in the first-line treatment of advanced non-small cell lung cancer with EGFR mutation.","authors":"Lili Su, Xiangyu Zhang, Mengrong Li, Ying Li, Dong Wang","doi":"10.1080/14737167.2025.2518135","DOIUrl":"10.1080/14737167.2025.2518135","url":null,"abstract":"Objective: To evaluate the cost-effectiveness of osimertinib compared to dacomitinib for advanced non-small cell lung cancer with EGFR mutation from the perspective of China's health system.Methods: Based on the FLAURA clinical trial and network meta-analysis, a partitioned survival model was constructed with a model simulation timeframe of 10 years and a 3-week cycle. Cost and quality-adjusted life years (QALYs) were used as model output indicators, and the incremental cost-effectiveness ratio was calculated to determine the economic feasibility of osimertinib compared to dacomitinib through cost-utility analysis. Sensitivity analysis was applied to test the robustness of the model.Results: The basic analysis results indicate that the osimertinib group incurred an additional cost of 138,487 Chinese Yuan (CNY) compared to the dacomitinib group, but gained an additional 0.32 QALYs. The incremental cost-effectiveness ratio is 436,203 CNY, which is higher than three times China's per capita GDP.Conclusion: Under the threshold of three times China's per capita GDP, osimertinib appears not to be cost-effective compared to dacomitinib.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-8"},"PeriodicalIF":1.8,"publicationDate":"2025-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144247213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Determinants of cancer drug prices in Germany and France: a multiple regression analysis. 德国和法国抗癌药物价格的决定因素：多元回归分析。

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-06-12 DOI: 10.1080/14737167.2025.2518140

Nethra Subramanian, Aadhav Subramanian

{"title":"Determinants of cancer drug prices in Germany and France: a multiple regression analysis.","authors":"Nethra Subramanian, Aadhav Subramanian","doi":"10.1080/14737167.2025.2518140","DOIUrl":"10.1080/14737167.2025.2518140","url":null,"abstract":"Background: Higher prices for drugs targeting rarer cancers may be justified, but the extent remains uncertain. This research analyses the determinants of cancer drug prices in Germany and France.Research design and methods: Cancer drugs approved in EU between 2011 and 2022 with available benefit assessments and prices were analyzed. Monthly treatment cost was the dependent variable; approval year, orphan status, benefit rating, number of comparators, and target population size were independent variables. Univariate and multiple regression analyses were conducted.Results: The analysis included 107 drugs in Germany and 70 in France. In Germany, univariate analysis showed significance for benefit magnitude, orphan status, number of comparators, target population, and approval year. In France, orphan status, number of comparators, target population, and approval year were significant. Regression models showed that log target population (p < 0.0001), approval year (p = 0.021), and major/considerable benefit (p < 0.0001) were significant in Germany; log target population (p = 0.001) and ASMR II/III (p = 0.017) were significant in France.Conclusions: Target population and benefit rating are drivers of cancer drug prices in Germany and France. The analysis provides quantitative evidence on the association between cancer rarity and price, which could inform policy.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-8"},"PeriodicalIF":1.8,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144247214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Autologous stem-cell transplantation and maintenance therapy for transplant-eligible multiple myeloma patients: cost-effectiveness analysis based on a network meta-analysis. 自体干细胞移植和维持治疗适合移植的多发性骨髓瘤患者：基于网络荟萃分析的成本-效果分析

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-06-01 Epub Date: 2025-02-05 DOI: 10.1080/14737167.2025.2461636

Weijia Wu, Yannan Wang, Yingting Lou, Xiaoyuan Fan, Wenqianzi Yang, Fengyuan Tang, Zixuan Zhao, Hengjin Dong

{"title":"Autologous stem-cell transplantation and maintenance therapy for transplant-eligible multiple myeloma patients: cost-effectiveness analysis based on a network meta-analysis.","authors":"Weijia Wu, Yannan Wang, Yingting Lou, Xiaoyuan Fan, Wenqianzi Yang, Fengyuan Tang, Zixuan Zhao, Hengjin Dong","doi":"10.1080/14737167.2025.2461636","DOIUrl":"10.1080/14737167.2025.2461636","url":null,"abstract":"Background: This study aimed to evaluate the cost-effectiveness of ASCT and maintenance therapy strategies for transplant-eligible patients with newly diagnosed multiple myeloma from a Chinese healthcare perspective.Research design and methods: A short-run decision tree and a long-run Markov model were created to assess the mean costs and quality-adjusted life-years (QALYs) of ASCT plus maintenance therapy over a lifetime horizon. Utility values were sourced from published literature, while healthcare costs were based on a single-center retrospective analysis and national drug bidding data.Results: The ASCT strategy with two-year daratumumab maintenance had the lowest discounted costs (1,394,183 CNY). Compared to no ASCT with continuous lenalidomide maintenance, ASCT had an ICER of 90,997 CNY/QALY. With one-year lenalidomide maintenance, ASCT provided more QALYs at lower costs. One-year lenalidomide maintenance after ASCT also resulted in higher QALYs and lower costs than no maintenance, while continuous lenalidomide had an ICER of 396,731 CNY/QALY.Conclusions: Under the WTP threshold of CNY 268,074 per QALY, ASCT strategies were more cost-effective than non-ASCT approaches. One-year lenalidomide therapy after ASCT was more cost-effective than no maintenance or continuous therapy. Among all strategies, ASCT followed by two years of daratumumab maintenance was the most cost-effective option.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"697-707"},"PeriodicalIF":1.8,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143188816","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-06-01 Epub Date: 2025-03-26 DOI: 10.1080/14737167.2025.2482661

Carlo Lazzaro, Giovanni Fattore, Angelo Guido Corsico

{"title":"COVID-19-related hospitalizations in Italy: an application of the synthetic control method to investigate the trajectory of diagnosis-related group 79 and its counterfactual during 2010-2021.","authors":"Carlo Lazzaro, Giovanni Fattore, Angelo Guido Corsico","doi":"10.1080/14737167.2025.2482661","DOIUrl":"10.1080/14737167.2025.2482661","url":null,"abstract":"Background: With 10.95 million cases (11 March 2020-9 February 2022), Italy was massively hit by the coronavirus disease 2019 (COVID-19) pandemic. Most of the COVID-19-related inpatient discharges were codified under the Diagnosis-Related Group (DRG) 79. During 2019-2021, DRG 79 inpatient discharges increased from 20,377 to 130,580 (+540.82%).Research design and methods: To investigate the causal relationship between DRG 79 inpatient discharges and COVID-19, the synthetic control method (SCM) compared the real with the counterfactual DRG 79. The latter was a weighted combination of control units (22 DRGs unrelated to COVID-19). The SCM mimicked the trajectory of DRG 79 in the absence of COVID-19.Placebo studies and robustness test investigated the reliability of the baseline findings.Results: Six out of the 22 control units contribute to the counterfactual DRG 79. The real and the counterfactual DRG 79 cease to overlap from 2019 onward. Placebo studies and robustness test confirm the causal relationship of COVID-19 with the increased number of inpatient discharges coded under DRG 79 during 2019-2021.Conclusion: The SCM identifies a causal link between COVID-19 and DRG 79 in Italy. Hopefully, future contributions will utilize SCM (and causal inference in general) in health care decision-making within the Italian National Health Service.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"781-793"},"PeriodicalIF":1.8,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143673540","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cardiovascular events, mortality, and incident type 2 diabetes in patients with metabolic dysfunction-associated steatohepatitis: a claims-based analysis of commercial and Medicare Advantage enrollees. 代谢功能障碍相关脂肪性肝炎患者的心血管事件、死亡率和2型糖尿病：一项基于索赔的商业和医疗保险优势参保者分析

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-06-01 Epub Date: 2025-04-13 DOI: 10.1080/14737167.2025.2490303

Semiu O Gbadamosi, Jason P Swindle, Hai Nguyen, Qian Li, Anthony Hoovler

{"title":"Cardiovascular events, mortality, and incident type 2 diabetes in patients with metabolic dysfunction-associated steatohepatitis: a claims-based analysis of commercial and Medicare Advantage enrollees.","authors":"Semiu O Gbadamosi, Jason P Swindle, Hai Nguyen, Qian Li, Anthony Hoovler","doi":"10.1080/14737167.2025.2490303","DOIUrl":"10.1080/14737167.2025.2490303","url":null,"abstract":"Background: The objective of this study was to examine the risks of cardiovascular events, incident type 2 diabetes (T2D), and mortality in patients with newly diagnosed metabolic dysfunction-associated steatohepatitis (MASH) compared with those without MASH in a large real-world setting in the US.Methods: We retrospectively analyzed US claims data from Optum®'s de-identified Clinformatics® Data Mart database from October 2015 to December 2022. Patients with newly diagnosed MASH were matched 1:1 on age, sex, region, and index month-year with patients without MASH, and repeated for a subgroup without baseline diabetes. Risks of clinical outcomes associated with MASH were assessed using Cox proportional hazard models.Results: The study comprised 24,278 matched pairs in the patients with and without MASH cohorts. Patients with MASH had increased risks for any cardiovascular event (adjusted HR: 1.48 [95% CI = 1.38-1.58]), and all-cause mortality (1.31; 1.20-1.42) compared to those without MASH. For the subgroup without baseline diabetes (10,027 matched pairs), the adjusted HRs were 1.94 (95% CI = 1.68-2.23) for incident T2D and 1.40 (95% CI = 1.20-1.64) for all-cause mortality.Conclusion: Our findings suggest increased risks of cardiovascular events, incident T2D, and mortality among patients newly diagnosed with MASH compared with patients without MASH.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"823-832"},"PeriodicalIF":1.8,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143989736","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Medical oncologists' dance with international guidelines and national reimbursement: insights from a survey in Türkiye. 医学肿瘤学家与国际指导方针和国家报销的舞蹈：来自<s:1> rkiye调查的见解。

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-06-01 Epub Date: 2025-02-04 DOI: 10.1080/14737167.2025.2462238

Ozgur Tanriverdi, Melek Ozdemir, Emre Hafizoglu, Taliha Guclu, Elvina Almurodova, Sait Kitapli, Islam Cagri Bosna, Tugba Dubektas-Canbek, Utku Oflazoglu, Ali Alkan, Sabri Barutca

{"title":"Medical oncologists' dance with international guidelines and national reimbursement: insights from a survey in Türkiye.","authors":"Ozgur Tanriverdi, Melek Ozdemir, Emre Hafizoglu, Taliha Guclu, Elvina Almurodova, Sait Kitapli, Islam Cagri Bosna, Tugba Dubektas-Canbek, Utku Oflazoglu, Ali Alkan, Sabri Barutca","doi":"10.1080/14737167.2025.2462238","DOIUrl":"10.1080/14737167.2025.2462238","url":null,"abstract":"Background: This study explores Turkish medical oncologists' perceptions of integrating international treatment guidelines with national reimbursement policies, considering local legal, economic, and healthcare constraints.Research design and methods: A cross-sectional online survey was conducted from March 24-31, 2024, targeting all 1,096 active oncologists registered with the Turkish Medical Oncology Association, as these specialists are exclusively authorized to prescribe anticancer drugs under national regulations. The survey included 25 questions on demographics, perceptions of guidelines, and integration preferences. Statistical analyses, including chi-square tests and logistic regression, identified factors influencing guideline preferences.Results: Among 337 respondents (31%), 94% found international guidelines essential, but 62% noted a lack of clear real-world algorithms. Significant predictors for preferring national guidelines included working in public institutions (OR: 3.90, p < 0.001), concerns about pharmaceutical industry influence (OR: 4.38, p = 0.017), legal challenges (OR: 5.89, p < 0.001), and variability among clinical research centers (OR: 2.95, p = 0.019). Despite these challenges, 57% favored national guidelines for their compatibility with local healthcare policies.Conclusions: The findings highlight the need for hybrid models that merge the evidence-based rigor of international frameworks with local healthcare priorities. Such models can enhance equitable and effective cancer care in Türkiye by addressing both global standards and national realities.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"709-719"},"PeriodicalIF":1.8,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143079210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0